Literature DB >> 18489713

The roles of membrane estrogen receptor subtypes in modulating dopamine transporters in PC-12 cells.

Rebecca A Alyea1, Stephanie E Laurence, Sung H Kim, Benita S Katzenellenbogen, John A Katzenellenbogen, Cheryl S Watson.   

Abstract

The effects of 17beta-estradiol (E(2)) on dopamine (DA) transport could explain gender and life-stage differences in the incidence of some neurological disorders. We tested the effects of E(2) at physiological concentrations on DA efflux in nerve growth factor-differentiated rat pheochromocytoma cells that express estrogen receptors (ER) alpha, ERbeta, and G-protein coupled receptor 30 (GPR30), and DA transporter (DAT). DAT efflux was determined as the transporter-specific loss of (3)H-DA from pre-loaded cells; a 9-15 min 10(-9 )M E(2) treatment caused maximal DA efflux. Such rapid estrogenic action suggests a non-genomic response, and an E(2)-dendrimer conjugate (limited to non-nuclear actions) caused DA efflux within 5 min. Efflux dose-responses for E(2) were non-monotonic, also characteristic of non-genomic estrogenic actions. ERalpha siRNA knockdown abolished E(2)-mediated DA efflux, while ERbeta knockdown did not, and GPR30 knockdown increased E(2)-mediated DA efflux (suggesting GPR30 is inhibitory). Use of ER-selective agonists/antagonists demonstrated that ERalpha is the predominant mediator of E(2)-mediated DA efflux, with inhibitory contributions from GPR30 and ERbeta. E(2) also caused trafficking of ERalpha to the plasma membrane, trafficking of ERbeta away from the plasma membrane, and unchanged membrane GPR30 levels. Therefore, ERalpha is largely responsible for non-genomic estrogenic effects on DAT activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18489713      PMCID: PMC2574842          DOI: 10.1111/j.1471-4159.2008.05491.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  47 in total

Review 1.  Estrogen actions in the central nervous system.

Authors:  B S McEwen; S E Alves
Journal:  Endocr Rev       Date:  1999-06       Impact factor: 19.871

Review 2.  New insights into the mechanism of action of amphetamines.

Authors:  Annette E Fleckenstein; Trent J Volz; Evan L Riddle; James W Gibb; Glen R Hanson
Journal:  Annu Rev Pharmacol Toxicol       Date:  2007       Impact factor: 13.820

Review 3.  Contribution of estrogen receptors alpha and beta to the effects of estradiol in the brain.

Authors:  M Morissette; M Le Saux; M D'Astous; S Jourdain; S Al Sweidi; N Morin; E Estrada-Camarena; Pablo Mendez; Luis Miguel Garcia-Segura; T Di Paolo
Journal:  J Steroid Biochem Mol Biol       Date:  2007-09-07       Impact factor: 4.292

4.  Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-alpha-selective agonists.

Authors:  S R Stauffer; C J Coletta; R Tedesco; G Nishiguchi; K Carlson; J Sun; B S Katzenellenbogen; J A Katzenellenbogen
Journal:  J Med Chem       Date:  2000-12-28       Impact factor: 7.446

5.  Lack of relationship between the HLA system and subacute sclerosing panencephalitis.

Authors:  A Cztonkowska; M Klos; B Iwińska
Journal:  Acta Neurol Scand       Date:  1986-03       Impact factor: 3.209

6.  Nuclear mechanisms of estrogen action. Effects of estradiol and anti-estrogens on estrogen receptors and nuclear receptor processing.

Authors:  K B Horwitz; W L McGuire
Journal:  J Biol Chem       Date:  1978-11-25       Impact factor: 5.157

7.  Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation.

Authors:  E T Alarid; N Bakopoulos; N Solodin
Journal:  Mol Endocrinol       Date:  1999-09

8.  Response-specific and ligand dose-dependent modulation of estrogen receptor (ER) alpha activity by ERbeta in the uterus.

Authors:  Jonna Frasor; Daniel H Barnett; Jeanne M Danes; Rex Hess; Albert F Parlow; Benita S Katzenellenbogen
Journal:  Endocrinology       Date:  2003-07       Impact factor: 4.736

Review 9.  Influence of estrogens on neurodegenerative processes.

Authors:  Anna Członkowska; Agnieszka Ciesielska; Ilona Joniec
Journal:  Med Sci Monit       Date:  2003-10

10.  Pilot study on the effect of estrogen replacement therapy on brain dopamine transporter availability in healthy, postmenopausal women.

Authors:  Sara A Gardiner; Mary F Morrison; P David Mozley; Lyn Harper Mozley; Colleen Brensinger; Warren Bilker; Andrew Newberg; Michelle Battistini
Journal:  Am J Geriatr Psychiatry       Date:  2004 Nov-Dec       Impact factor: 4.105

View more
  35 in total

1.  GPR30 regulates glutamate transporter GLT-1 expression in rat primary astrocytes.

Authors:  Eunsook Lee; Marta Sidoryk-Wêgrzynowicz; Ning Wang; Anton Webb; Deok-Soo Son; Kyuwon Lee; Michael Aschner
Journal:  J Biol Chem       Date:  2012-05-29       Impact factor: 5.157

Review 2.  Nongenomic signaling pathways of estrogen toxicity.

Authors:  Cheryl S Watson; Yow-Jiun Jeng; Mikhail Y Kochukov
Journal:  Toxicol Sci       Date:  2009-12-02       Impact factor: 4.849

3.  Ligand Accessibility and Bioactivity of a Hormone-Dendrimer Conjugate Depend on pH and pH History.

Authors:  Sung Hoon Kim; Zeynep Madak-Erdogan; Sung Chul Bae; Kathryn E Carlson; Christopher G Mayne; Steve Granick; Benita S Katzenellenbogen; John A Katzenellenbogen
Journal:  J Am Chem Soc       Date:  2015-08-10       Impact factor: 15.419

Review 4.  International Union of Basic and Clinical Pharmacology. XCVII. G Protein-Coupled Estrogen Receptor and Its Pharmacologic Modulators.

Authors:  Eric R Prossnitz; Jeffrey B Arterburn
Journal:  Pharmacol Rev       Date:  2015-07       Impact factor: 25.468

5.  Lack of consistent sex differences in D-amphetamine-induced dopamine release measured with [18F]fallypride PET.

Authors:  Christopher T Smith; Linh C Dang; Leah L Burgess; Scott F Perkins; M Danica San Juan; Darcy K Smith; Ronald L Cowan; Nam T Le; Robert M Kessler; Gregory R Samanez-Larkin; David H Zald
Journal:  Psychopharmacology (Berl)       Date:  2018-10-22       Impact factor: 4.530

Review 6.  Signaling, physiological functions and clinical relevance of the G protein-coupled estrogen receptor GPER.

Authors:  Eric R Prossnitz; Matthias Barton
Journal:  Prostaglandins Other Lipid Mediat       Date:  2009-05-13       Impact factor: 3.072

7.  Combinations of physiologic estrogens with xenoestrogens alter calcium and kinase responses, prolactin release, and membrane estrogen receptor trafficking in rat pituitary cells.

Authors:  Yow-Jiun Jeng; Mikhail Kochukov; Cheryl S Watson
Journal:  Environ Health       Date:  2010-10-15       Impact factor: 5.984

8.  Direct estradiol and diethylstilbestrol actions on early- versus late-stage prostate cancer cells.

Authors:  Luke Y Koong; Cheryl S Watson
Journal:  Prostate       Date:  2014-09-11       Impact factor: 4.104

9.  Differential regulation of dopamine transporter function and location by low concentrations of environmental estrogens and 17beta-estradiol.

Authors:  Rebecca A Alyea; Cheryl S Watson
Journal:  Environ Health Perspect       Date:  2009-01-05       Impact factor: 9.031

10.  Nongenomic mechanisms of physiological estrogen-mediated dopamine efflux.

Authors:  Rebecca A Alyea; Cheryl S Watson
Journal:  BMC Neurosci       Date:  2009-06-16       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.